

## Faculty Council Intellectual Property Committee Report

Craig M. Lilly, MD, Chair

University of Massachusetts Chan Medical School Intellectual Property Committee

February 6, 2025

# 2024 Areas of Focus

- 1. To increase faculty awareness of the available intellectual property development resources that our University provides.
- 2. To review the programs of the Office of Innovation and Business Development and provide our business development leadership with actionable feedback to maximize the use and utility of these valuable resources.
- 3. To solicit and review faculty concerns related to intellectual property and work through Dr. Fitzgerald to communicate validated and significant issues to our senior leaders.



# **BRIDGE Program Essentials**

#### -The United States Patent Office determines inventorship using a

#### first-to-file system rather than a first-to-invent system

#### -BRIDGE engagement starts with Invention Disclosure which

launches the commercialization process.

## Another successful year 2023/2024



CONFIDENTIAL | 4

# Innovator Feedback

Comments from faculty who have interacted with our BRIDGE program have been strongly positive.

There have been no faculty concerns identified during 2024 that required communication with our senior leadership.

2024 Intellectual Property Committee Annual Report, meeting minutes and this presentation have provided as attachments for inclusion with the Faculty Council Meeting minutes

# Optimizing intellectual property is like oncology, early identification and management with a with a team of specialists results in the best outcomes.

Craig M. Lilly, MD



## **Approved Products**













#### **ZINPLA** (bezlotoxumab) Injection 25 mg/mL







23 June 1960

Enovid, world's first oral contraceptive, approved.



### **UMass Chan Start-Ups**







2/Alnylam<sup>®</sup>20











#### generation bio

